Literature DB >> 15877072

Tunable antibodies.

Louis M Weiner, Paul Carter.   

Abstract

Mesh：

Substances：

Year:  2005        PMID： 15877072     DOI： 10.1038/nbt0505-556

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  15 in total

Review 1.  Molecular engineering of antibodies for therapeutic and diagnostic purposes.

Authors:  Frédéric Ducancel; Bruno H Muller
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

2.  Making antibodies from scratch.

Authors:  J Christopher Love
Journal:  Nat Biotechnol       Date:  2010-11       Impact factor: 54.908

3.  Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies.

Authors:  Carlos Vaccaro; Roger Bawdon; Sylvia Wanjie; Raimund J Ober; E Sally Ward
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-20       Impact factor: 11.205

4.  Engineered antibody Fc variants with enhanced effector function.

Authors:  Greg A Lazar; Wei Dang; Sher Karki; Omid Vafa; Judy S Peng; Linus Hyun; Cheryl Chan; Helen S Chung; Araz Eivazi; Sean C Yoder; Jost Vielmetter; David F Carmichael; Robert J Hayes; Bassil I Dahiyat
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-06       Impact factor: 11.205

Review 5.  Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn.

Authors:  E Sally Ward; Raimund J Ober
Journal:  Adv Immunol       Date:  2009       Impact factor: 3.543

6.  Monoclonal antibody to six transmembrane epithelial antigen of prostate-4 influences insulin sensitivity by attenuating phosphorylation of P13K (P85) and Akt: possible mitochondrial mechanism.

Authors:  Da-ni Qin; Jin-Gai Zhu; Chen-bo Ji; Chun-zhao Kou; Guan-zhong Zhu; Chun-Mei Zhang; Yan-Ping Wang; Yu-hui Ni; Xi-rong Guo
Journal:  J Bioenerg Biomembr       Date:  2011-06-07       Impact factor: 2.945

Review 7.  Immunotherapy of cancer.

Authors:  Hossein Borghaei; Mitchell R Smith; Kerry S Campbell
Journal:  Eur J Pharmacol       Date:  2009-10-20       Impact factor: 4.432

8.  Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy.

Authors:  Liat Binyamin; R Katherine Alpaugh; Tracey L Hughes; Charles T Lutz; Kerry S Campbell; Louis M Weiner
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

9.  In vivo biodistribution, PET imaging, and tumor accumulation of 86Y- and 111In-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice.

Authors:  Douglas W Schneider; Tara Heitner; Bruno Alicke; David R Light; Kirk McLean; Noboru Satozawa; Gordon Parry; Jeongsoo Yoo; Jason S Lewis; Renate Parry
Journal:  J Nucl Med       Date:  2009-02-17       Impact factor: 10.057

Review 10.  Interactions of tumor cells with dendritic cells: balancing immunity and tolerance.

Authors:  M V Dhodapkar; K M Dhodapkar; A K Palucka
Journal:  Cell Death Differ       Date:  2007-10-19       Impact factor: 15.828
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.